FDA Import Refusal 1FX-0916594-6/10002/1 — Boehringer Ingelheim Pharma GmbH & Co. KG
The FDA refused shipment 1FX-0916594-6/10002/1 from Boehringer Ingelheim Pharma GmbH & Co. KG (Germany) on Sep 18, 2026. The refused product falls under Drugs and Biologics — EMPAGLIFLOZIN (ANTI-DIABETIC). Cited charge: 75 This firm has 5 or more other import refusals on record.
Refusal Details
- Date
- Sep 18, 2026
- Country
- Germany
- Product Category
- Drugs and Biologics
- Product Code
- 61PCB73 EMPAGLIFLOZIN (ANTI-DIABETIC)
- Charges
- 75